Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cybin Inc. Common Shares (NY:CYBN)

8.280 UNCHANGED
Last Price Updated: 8:00 PM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cybin Inc. Common Shares

< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
41 42 Next >
News headline image
Cybin Announces Renewed At-The-Market Equity Program of up to US$35 Million
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO Featured in Proactive Interview
Via Investor Brand Network
Topics Intellectual Property
News headline image
Psyched: Fed Study On Psychedelics, Janet Yellen's Magic Mushrooms, Financing Deals & Quarterly Reports ↗
Cannabis, Psychedelics Use And Binge Drinking At All-Time High Among Adults, Teens Remain Stable, Fed Study Finds 
Via Benzinga
Topics Cannabis Economy
News headline image
6 Analysts Have This to Say About Cybin ↗
 
Via Benzinga
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Begins Preparing for CYB003 Capsule Manufacturing for Potential Phase 3 Trial
Via Investor Brand Network
News headline image
Cybin Prepares for GMP Manufacturing of CYB003 Capsules for Phase 3 Trial
From Cybin Inc.
Via Business Wire
News headline image
Psychedelics IP Protection: Cybin Nabs US Patent For Deuterated Analogs, Psilera Advances Next-Gen Library ↗
Cybin’s New US Patent Covers Proprietary Deuterated Psychedelic Analogs 
Via Benzinga
Topics Intellectual Property
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Secures New US Patent Supporting Its CYB003 Program
Via Investor Brand Network
Topics Intellectual Property
News headline image
Cybin Announces Grant of U.S. Patent Covering Proprietary Deuterated Psilocybin Analog in its CYB003 Program
From Cybin Inc.
Via Business Wire
News headline image
Cybin's Q1 2023 Financials, Deuterated Psychedelics Moving 'Steadily' Through The Clinic ↗
Canadian clinical-stage psychedelics company Cybin (NYSE: CYBN) shared its unaudited financial results for the first quarter ended June 30, 2023: 
Via Benzinga
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Q1 2024 Financial Results, Business Highlights
Via Investor Brand Network
News headline image
Psyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & More ↗
First Ever Professional Practice Guidelines For Psychedelic-Assisted Therapy Published 
Via Benzinga
News headline image
Cybin Reports First Quarter Financial Results and Recent Business Highlights
From Cybin Inc.
Via Business Wire
News headline image
Cybin Closes Short-Lasting Overnight Public Offering With Top Issuance For $8.25M ↗
Psychedelics biotech Cybin Inc. (NYSE: CYBN) closed its recently announced overnight marketed public offering with an aggregate of 24,264,706 units 
Via Benzinga
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Closing of Marketed Public Offering
Via Investor Brand Network
News headline image
Cybin Announces Closing of Overnight Marketed Public Offering of Units
From Cybin Inc.
Via Business Wire
News headline image
Psyched: Portugal Decriminalizes Synthetic Drugs, Anorexia And Psilocybin, LSD Microdosing, California & More ↗
A Revolutionary Approach: Portugal Decriminalizes Synthetic Drugs Portugal’s Parliament recently decriminalized the use of synthetic drugs. The new law equates the legal treatment of these substances... 
Via Benzinga
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Details About Public Offering, Begins Dosing in Final Phase 2 Trial Cohort
Via Investor Brand Network
News headline image
Cybin Initiates Dosing of Final Cohort of its Phase 2 Trial of CYB003 in Major Depressive Disorder
From Cybin Inc.
Via Business Wire
News headline image
Cybin Launches 3-Day Overnight Public Offering For Up To $8.25M, Suspends Prior Purchase Deal ↗
Psychedelics company Cybin Inc. (NYSE: CYBN) announced an overnight marketed public offering of its units and confirmed its set pricing on an aggregate 24,264,706 Cybin units, at $0.34 each, for... 
Via Benzinga
News headline image
Why Aaron's Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) shares gained 188.8% to $4.13. The stock is now on the Regulation SHO "threshold security" list. 
Via Benzinga
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Launches Overnight Public Offering
Via Investor Brand Network
News headline image
US Stocks Mixed; Pfizer Earnings Beat Views ↗
U.S. stocks were mixed this morning, with the Dow Jones trading slightly higher on Tuesday. Following the market opening Tuesday, the Dow traded up 0.03% to 35,568.68 while the NASDAQ fell 0.57% to... 
Via Benzinga
News headline image
Cybin Announces Size and Pricing of Previously Announced Overnight Marketed Public Offering of Units
From Cybin Inc.
Via Business Wire
News headline image
Why TETRA Technologies Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket ↗
Gainers American Superconductor Corporation (NASDAQ: AMSC) shares surged 112.1% to $21.38 in pre-market trading. AMSC is expected to report first-quarter results on Aug. 9, 2023. 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗
It's time for a look at the biggest pre-market stock movers as we check out the latest news worth reading on Tuesday morning! 
Via InvestorPlace
News headline image
Cybin Announces Overnight Marketed Public Offering of Units
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Plans to Participate in Annual Canaccord Genuity Growth Conference
Via Investor Brand Network
News headline image
Cybin to Participate in the Canaccord Genuity 43rd Annual Growth Conference
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), Global CRO Partner to Study, Develop CYB003 as Effective MDD Treatment
Via Investor Brand Network
< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
41 42 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.